HER2 mutation profiling in mucinous ovarian carcinoma: Inferences for Enhertu (trastuzumab deruxtecan) as a potential therapeutic approach
Our findings reveal a high prevalence of HER2 mutations in mOC, with distinct profiles in TKD and non-TKD regions. These results support further investigation of Enhertu (T-DXd) as a promising targeted therapy for HER2-mutant mOC. Larger, multi-center studies are needed to validate these findings and explore clinical applications.
Authors
- Gwo‐Tarng Sheu (ORCID: https://orcid.org/0000-0002-1299-3375)
- Wan‐Ru Chao (ORCID: https://orcid.org/0000-0002-2417-9979)
- Ming‐Yung Lee (ORCID: https://orcid.org/0000-0002-3617-9423)
- Huang‐Pin Shen
- Yi-Ju Lee (ORCID: https://orcid.org/0000-0002-7470-4233)
- Chih‐Ping Han
Institutions
- Providence University (TW)
- Chung Shan Medical University Hospital (TW)
- Chung Shan Medical University (TW)
Publication Details
- Journal
- Taiwanese Journal of Obstetrics and Gynecology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1016/j.tjog.2025.04.013
- Citations
- 2
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 2.09